Table 4.
Platelet Counts Before and After rhIL-11
| Study Subject | Platelet Count(No./μl) | ||||
|---|---|---|---|---|---|
| Pt | Age/Sex | Diagnosis | Pre | Day 4 | Day 10 |
| VWD Patients | |||||
| #1 | 25/F | 1 VWD | 227,000 | 180,000 | 298,000 |
| #2 | 22/F | 2B VWD | NA (clumped)* | 22,000 | NA (clumped)* |
| #3 | 25/F | 1 VWD | 217,000 | 215,000 | 201,000 |
| #7 | 26F | 2M VWD | 266,000 | 200,000 | 333,000 |
| Fold Increase | 0.84-fold | 1.17-fold | |||
| Hemophilia A Patients | |||||
| #4 | 25/M | Mild HA | 307,000 | 250,000 | 399,000 |
| #5 | 51/M | Mild HA | 181,000 | 132,000 | 202,000 |
| #6 | 31/M | Mild HA | 221,000 | 184,000 | 270,000 |
| #8 | 26/M | Mild HA | 250,000 | 231,000 | 377,000 |
| #9 | 34/M | Mod HA | 274,000 | 224,000 | 364,000 |
| Fold Increase | 0.83-fold | 1.31-fold | |||
VWD is von Willebrand disease; Dx is diagnosis; HA is hemophilia A; rhIL-11 is recombinant interleukin-11; NA is not available. The day 4 platelet count was obtained at 30 minutes following the fourth of four consecutive daily doses of rhIL-11, while the Day 10 platelet count was obtained 10 days after the first dose (or 6 days after the final dose of rhIL-11). It should be noted that while plateletsclumped in the single patient with 2B VWD, basal platelet count are in the 20,000/μlrange, most recently 26,000/μl, indicating no increaseoccurred after rhIL-11.